Akebia Therapeutics Inc (AKBA)
1.86
-0.06
(-3.12%)
USD |
NASDAQ |
Nov 14, 16:00
1.865
0.00 (0.00%)
After-Hours: 20:00
Akebia Therapeutics Cash from Financing (Quarterly): 1.223M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.223M |
| June 30, 2024 | 7.64M |
| March 31, 2024 | 18.48M |
| December 31, 2023 | -1.29M |
| September 30, 2023 | 0.05M |
| June 30, 2023 | -8.00M |
| March 31, 2023 | -15.97M |
| December 31, 2022 | -0.001M |
| September 30, 2022 | -32.94M |
| June 30, 2022 | -0.009M |
| March 31, 2022 | 47.54M |
| December 31, 2021 | 5.403M |
| September 30, 2021 | 16.48M |
| June 30, 2021 | 37.37M |
| March 31, 2021 | 74.48M |
| December 31, 2020 | 30.51M |
| September 30, 2020 | 1.054M |
| June 30, 2020 | 142.81M |
| March 31, 2020 | 57.35M |
| December 31, 2019 | 94.42M |
| September 30, 2019 | 0.195M |
| June 30, 2019 | 8.804M |
| March 31, 2019 | -14.45M |
| December 31, 2018 | 0.085M |
| Date | Value |
|---|---|
| September 30, 2018 | 0.354M |
| June 30, 2018 | 0.212M |
| March 31, 2018 | 95.91M |
| December 31, 2017 | 5.243M |
| September 30, 2017 | 63.78M |
| June 30, 2017 | 45.47M |
| March 31, 2017 | 1.746M |
| December 31, 2016 | 3.529M |
| September 30, 2016 | 2.329M |
| June 30, 2016 | -0.094M |
| March 31, 2016 | 61.18M |
| December 31, 2015 | 4.34M |
| September 30, 2015 | 13.95M |
| June 30, 2015 | 64.75M |
| March 31, 2015 | 0.049M |
| December 31, 2014 | -0.048M |
| September 30, 2014 | -0.125M |
| June 30, 2014 | -1.181M |
| March 31, 2014 | 105.75M |
| December 31, 2013 | -0.215M |
| September 30, 2013 | -0.0408M |
| June 30, 2013 | 40.10M |
| March 31, 2013 | 2.483M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-32.94M
Minimum
Sep 2022
142.81M
Maximum
Jun 2020
23.83M
Average
6.522M
Median
Cash from Financing (Quarterly) Benchmarks
| Corcept Therapeutics Inc | -21.09M |
| Bioventus Inc | 0.362M |
| Eli Lilly and Co | 211.30M |
| NovaBay Pharmaceuticals Inc | 2.089M |
| Palatin Technologies Inc | 5.991M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -6.695M |
| Cash from Investing (Quarterly) | -0.002M |
| Free Cash Flow | -38.53M |
| Free Cash Flow Per Share (Quarterly) | -0.0318 |
| Free Cash Flow to Equity (Quarterly) | -7.021M |
| Free Cash Flow Yield | -10.17% |